Exploring the In Vitro Anticancer and Cytotoxic Potentials of Ruthenium(II)-Bathophenanthroline-Triazole Complex on MDA-MB-231 and Normal L6 Cell Lines

Anticancer complexes featuring ruthenium show potential as effective antitumor agents due to their minimal systematic toxicity and diverse chemical structures. The anticancer and cytotoxic potential of [Ru(bphen)2(apytrzSH)2]2+ complex (bphen = bathophenanthroline and apytrzSH = 4-amino-5-(4-pyridyl)-4H-1,2,4triazole-3-thiol) on MDA-MB-231 and normal L6 cells has been analysed by direct microscopic and MTT assay methods. The complex shows absorption peaks at 229, 276 and 450 nm. The formation [Ru(bphen)2(apytrzSH)2]2+ complex is confirmed from the FT-IR spectrum. The particle nature and the size of the synthesised complex is determined from the XRD analysis, and it is found to be polycrystalline with a particle size of 8.16 nm. The IC50 values of the complex on MDA-MB-231 and non-tumoral L6 cell lines are calculated from the cellular viability at different concentrations, and it is found to be 30.14 and 51.06 μg/mL. The cellular viability results indicate that the synthesised [Ru(bphen)2(apytrzSH)2]2+ complex has anticancer activity against MDA-MB-231 cell line and low cytotoxic effect against non-tumoral L6 cell line. Thus, the synthesized complex exhibits significant anticancer activity and can be employed for clinical diagnosis and therapeutic agents.